Skip to main
KYTX

KYTX Stock Forecast & Price Target

KYTX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kyverna Therapeutics is a promising clinical-stage biopharmaceutical company with a focused approach on developing cell therapies for autoimmune diseases. The company's recent positive results from the Phase 1 COMPARE study add to the potential upside for its lead product, KYV-101, in treating refractory rheumatoid arthritis (RA). With strong clinical and translational data, a positive regulatory outlook, and an estimated $800M in peak sales, Kyverna's future as a leader in the growing I&ICAR-T market looks bright.

Bears say

Kyverna Therapeutics is facing potential competition in the autoimmune disease market with an allogeneic therapy containing the same CAR as its current product, KYV-101. Additionally, the cost burden of $0.7M-$1.5M per patient and low success rate of its manufacturing support a negative outlook on the company's financials and margins. The company may struggle to maintain profitability and sustain long-term success in the market.

KYTX has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kyverna Therapeutics Inc (KYTX) Forecast

Analysts have given KYTX a Buy based on their latest research and market trends.

According to 4 analysts, KYTX has a Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kyverna Therapeutics Inc (KYTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.